A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate
the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects
with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort
1 and Cohort 2. Each cohort will enroll 30-60 cases.